Cited by 122Ovarian cancer diagnosis and treatmentCancer Cells and MetastasisReproductive Biology and Fertility

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies

Open access

Hernandez, Lidia, Kim, Marianne K., Lyle, L. Tiffany, Bunch, Kristen P., House, Carrie D., Ning, Franklin, Noonan, Anne M., Annunziata, Christina M.·2016·Gynecologic Oncology

DOI 10.1016/j.ygyno.2016.05.028PMC PMC4961516

Open this paper in CoChat — free account

Abstract

Objective The value of cell lines for pre-clinical work lies in choosing those with similar characteristics. Selection of cell lines is typically based on patient history, histological subtype at diagnosis, mutation patterns, or signaling pathways. Although recent studies established consensus regarding molecular characteristics of ovarian cancer cell lines, data on in vivo tumorigenicity remains only sporadically available, impeding translation of in vitro work to xenograft models.Methods We introduced 18 ovarian cancer cell lines into athymic nude mice through subcutaneous, intraperitoneal, and ovary intrabursal routes, and observed tumor development over 6weeks. We also profiled cell line gene expression and identified differentially expressed gene sets based on their ability to form tumors in the subcutaneous or intraperitoneal locations. Representative cell lines were further subjected to proteomic analyses.Results Ovarian cancer cell lines showed variable ability to grow in mice when implanted subcutaneous, intraperitoneal, or intrabursal. While some cell lines grew well in both SC and IP locations, others showed a strong propensity to grow in one location only. Gene expression profiles suggested that cell lines showing preference for IP growth had gene expression patterns more similar to primary tumors.Conclusions We report the tumorigenicity of 17 human ovarian cancer cell lines and one mouse cell line in three distinct anatomical locations, and associated gene networks. Growth patterns and histopathology, linked to molecular characteristics, provide a valuable resource to the research community, and better guide the choice of cell lines for in vitro studies to translate efficiently into xenograft testing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2016.05.028

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Ovarian Cancer Development and Metastasis
Lengyel, E. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,702
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,458
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,457
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies
Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939
Absence of HeLa Cell Contamination in 169 Cell Lines Derived From Human Tumors2
Fogh, J., Wright, W. C., & Loveless, J. D. (1977) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/58.2.209 · Cited by 663
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.
Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., Whang‐Peng, J., Rogan, A. M., Green, W. R., & Ozols, R. F. (1983) · PubMed · Cited by 539
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang‐Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., & Ozols, R. F. (1987) · PubMed · Cited by 498
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403 · cited 2×
“Recent studies have reported comprehensive data gathered for the most commonly available ovarian cancer cell lines (8, 9).”
Exome Capture Reveals ZNF423 and CEP164 Mutations, Linking Renal Ciliopathies to DNA Damage Response Signaling
Chaki, M., Airik, R., Ghosh, A. K., Giles, R. H., Chen, R., Slaats, G. G. G., Wang, H., Hurd, T. W., Zhou, W., Cluckey, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.028 · Cited by 390
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally–Raghavan, P., Miyake, T. M., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 306
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.
Bénard, J., Silva, J. D., Blois, M. C. D., Boyer, P. J. J., Duvillard, P., Chiric, E., & RIOU, G. F. (1985) · PubMed · Cited by 287
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Langdon, S. P., Lawrie, S. S., Hay, F. G., Hawkes, M. M., McDonald, A. W., Hayward, I. P., Schol, D. J., Hilgers, J., Leonard, R. C., & Smyth, J. F. (1988) · PubMed · Cited by 269
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C. M., Prentice, L., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072162 · Cited by 254
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Main, H. G., Xie, J., Lantvit, D. D., Cárdenas, H., Fang, F., Liu, Y., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.040 · Cited by 214
Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
Colombo, P., Fabbro, M., Theillet, C. G., Bibeau, F., Rouanet, P., & Ray-Coquard, I. L. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.017 · Cited by 193
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer
Schilder, R. J., HALL, L., Monks, A. P., Handel, L. M., Fornace, A. J., Ozols, R. F., Fojo, A. T., & Hamilton, T. C. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450306 · Cited by 185
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma
Cooke, S. L., Ng, C. K. Y., Melnyk, N., García, M. J., Hardcastle, T. J., Temple, J., Langdon, S. P., Huntsman, D. D., & Brenton, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.245 · Cited by 179
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors
Chenevix‐Trench, G., Ryland, G. L., Hunter, S. M., Doyle, M., Caramia, F., Li, J., Rowley, S. M., Christie, M., Allan, P. E., Stephens, A. N., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0210-y · Cited by 169
ORGANIZATION OF EXTRACELLULAR MATRIX COMPONENTS DURING DIFFERENTIATION OF ADIPOCYTES IN LONG-TERM CULTURE
Yasuaki, K. U. B. O., Kaidzu, S., Nakajima, I., Takenouchi, K., & NAKAMURA, F. (2000) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1071-2690(2000)036 · Cited by 133
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Role of maspin in cancer
Berardi, R., Morgese, F., Onofri, A., Mazzanti, P., Pistelli, M., Ballatore, Z., Savini, A., Lisa, M. D., Caramanti, M., Rinaldi, S., et al. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-8 · Cited by 122
DNA Methylation in Ovarian Cancer
Ahluwalia, A., Hurteau, J. A., Bigsby, R. M., & Nephew, K. P. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6284 · Cited by 118
Evidence for a Dualistic Model of High-grade Serous Carcinoma
Howitt, B. E., Hanamornroongruang, S., Lin, D. I., Conner, J. E., Schulte, S., Horowitz, N. S., Crum, C. P., & Meserve, E. E. K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000369 · Cited by 111
Gene Expression Correlations in Human Cancer Cell Lines Define Molecular Interaction Networks for Epithelial Phenotype
Kohn, K. W., Zeeberg, B. M., Reinhold, W. C., & Pommier, Y. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099269 · Cited by 109
Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy
Pepa, C. D., Tonini, G., Santini, D., Losito, S., Pisano, C., Napoli, M. D., Cecere, S. C., Gargiulo, P., & Pignata, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.003 · Cited by 97
Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research
Elias, K. M., Emori, M. M., Papp, E., MacDuffie, E., Konecny, G. E., Velculescu, V. E., & Drapkin, R. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.017 · Cited by 87
Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9
Lo, P. H. Y., Leung, A. C. C., Kwok, C. Y. C., Cheung, W. S. Y., Ko, J. M. Y., Yang, L., Law, S. Y.-K., Wang, L. D., Li, J., Stanbridge, E. J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209767 · Cited by 80
o,p′-DDD (mitotane) therapy of adrenal cortical carcinoma. Observations on drug dosage, toxicity, and steroid replacement
Hogan, T. F., Citrin, D. L., Johnson, B. M., Nakamura, S., Davis, T. E., & Borden, E. C. (1978) · Cancer · doi:10.1002/1097-0142(197811)42:5 · Cited by 72
IKK-ϵ Coordinates Invasion and Metastasis of Ovarian Cancer
Hsu, S. C., Kim, M., Hernandez, L. F., Grajales, V., Noonan, A. M., Anver, M. R., Davidson, B., & Annunziata, C. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3993 · Cited by 49
Self-citation
Serum S100A6 Concentration Predicts Peritoneal Tumor Burden in Mice with Epithelial Ovarian Cancer and Is Associated with Advanced Stage in Patients
Wei, B., Hoover, S. B., Ross, M. M., Zhou, W., Meani, F., Edwards, J. B., Spehalski, E. I., Risinger, J. I., Alvord, W. G., Quiñones, O. A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007670 · Cited by 47
Reliable in vitro studies require appropriate ovarian cancer cell lines
Jacob, F., Nixdorf, S., Hacker, N. F., & Heinzelmann-Schwarz, V. A. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-60 · Cited by 47
Overexpression of protease inhibitor‐dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo
Devoogdt, N., Rasool, N., Hoskins, E. R., Simpkins, F. A., Tchabo, N. E., & Kohn, E. C. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01076.x · Cited by 41
Glucocorticoids Stabilize HER-2/neu Messenger RNA in Human Epithelial Ovarian Carcinoma Cells
Karklan, B. Y., Jones, J., Slamon, D. J., & Lagasse, L. D. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1090 · Cited by 37
Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C. M., Prentice, L., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a · Cited by 36
Analysis of the Rb Gene and Cyclin-Dependent Kinase 4 Inhibitor Genes (p16INK4and p15INK4B) in Human Ovarian Carcinoma Cell Lines
Yaginuma, Y., Hayashi, H., Kawai, K., Kurakane, T., Saitoh, Y., Kitamura, S., Sengoku, K., & Ishikawa, M. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3560 · Cited by 32
In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
House, C. D., Hernandez, L. F., & Annunziata, C. M. (2015) · Journal of Visualized Experiments · doi:10.3791/52446 · Cited by 28
Self-citation
Knowledge-driven genomic interactions: an application in ovarian cancer
Kim, D., Li, R., DUDEK, S. M., Frase, A., Pendergrass, S. A., & Ritchie, M. D. (2014) · BioData Mining · doi:10.1186/1756-0381-7-20 · Cited by 23
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Nuñez-Cruz, S., Connolly, D. C., & Scholler, N. (2010) · Journal of Visualized Experiments · doi:10.3791/2146 · Cited by 18
Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21
Kim, M. K., Min, D. J., Wright, G. W., Goldlust, I. S., & Annunziata, C. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2665 · Cited by 14
Self-citation

Sorted by citations

Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms
van Weelden, G. H., Bobiński, M. S., Okła, K., van Weelden, W. J., Romano, A., & Pijnenborg, J. M. A. (2019) · Marine Drugs · doi:10.3390/md17010032 · Cited by 340
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response
Rickard, B. P., Conrad, C., Sorrin, A. J., Ruhi, M. K., Reader, J. C., Huang, S. A., Franco, W., Scarcelli, G., Polacheck, W. J., Roque, D. M., et al. (2021) · Cancers · doi:10.3390/cancers13174318 · Cited by 163
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
Hallas-Potts, A., Dawson, J. C., & Herrington, C. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41941-4 · Cited by 110
Activation of Wnt signaling promotes olaparib resistant ovarian cancer
Yamamoto, T. M., McMellen, A. N., Watson, Z. L., Aguilera, J., Ferguson, R. L., Nurmemmedov, E., Thakar, T., Moldovan, G., Kim, H., Cittelly, D. M., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23064 · Cited by 102
NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells
House, C. D., Jordan, E., Hernandez, L. F., Ozaki, M. K., James, J. M., Kim, M., Kruhlak, M. J., Batchelor, E., Elloumi, F., Cam, M. C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0366 · Cited by 94
Self-citation

See all 122

Authors: Hernandez, L., Kim, M. K., Lyle, L. T., Bunch, K. P., House, C. D., Ning, F., Noonan, A. M., & Annunziata, C. M.
Affiliations: National Cancer Institute (US)
Corresponding author: Annunziata, Christina M.
ORCID: Lyle, L. Tiffany
Bunch, Kristen P.
House, Carrie D.
Ning, Franklin
Noonan, Anne M.
Annunziata, Christina M.
Venue: Gynecologic Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 142
Issue: 2
Pages: 332-340
ISSN: 0090-8258 (ISSN-L)
DOI: 10.1016/j.ygyno.2016.05.028
PMC: PMC4961516
OpenAlex: W2399911066
Cited by: 121
References: 43
Citations by year: 2026: 10 · 2025: 10 · 2024: 15 · 2023: 16 · 2022: 17 · 2021: 15 · 2020: 17 · 2019: 14 · 2018: 4 · 2017: 3
FWCI: 9.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gynecologic Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute Intramural Research Program (ZIA BC 011054)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
Keywords: ovarian cancer cell lines, in vivo tumorigenicity, xenograft models, nude mice, subcutaneous implantation, intraperitoneal implantation, gene expression profiling, proteomic profiling, preclinical model selection
MeSH terms: Animals, Drug Screening Assays, Antitumor, Female, Humans, Neoplasm Transplantation, Ovarian Neoplasms, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks